Evaluating the impact of influenza vaccination and certain medications on COVID-19 outcomes
Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-CoV2 Infection
Consorci Sanitari de Terrassa · NCT04367883
This study is trying to see if getting the flu vaccine or taking certain medications helps people in the hospital recover better from COVID-19.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Sex | All |
| Sponsor | Consorci Sanitari de Terrassa (other) |
| Locations | 1 site (Terrassa, Barcelona) |
| Trial ID | NCT04367883 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess whether patients admitted to the Hospital de Terrassa who have received the influenza vaccine or are on treatments such as ACE inhibitors, ARBs, antihistamines, or amantadine show improved outcomes in their COVID-19 infection. The study will analyze hospital admissions, treatment histories, lengths of stay, ICU needs, and survival rates. By comparing these factors, the researchers hope to determine if these interventions can enhance patient recovery from COVID-19.
Who should consider this trial
Good fit: Ideal candidates for this study are patients admitted to the Hospital de Terrassa since March 1, 2020, regardless of the cause of admission.
Not a fit: Patients who have not been admitted to the Hospital de Terrassa or those from outside the reference area may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols for COVID-19, potentially saving lives and reducing hospitalizations.
How similar studies have performed: While some studies have suggested potential benefits of influenza vaccination and certain medications in COVID-19 outcomes, this specific approach remains novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause. Exclusion Criteria: * None. * For comparison of percentage of Influenza vaccination, ACEI and ARB vs general population, patients from outside the reference area of the Terrassa Health Consortium would be excluded.
Where this trial is running
Terrassa, Barcelona
- Hospital de Terrassa — Terrassa, Barcelona, Spain (RECRUITING)
Study contacts
- Principal investigator: Anna Puigdellívol-Sánchez, Ph D — Consorci Sanitari de Terrassa
- Study coordinator: Anna Puigdellívol-Sánchez, Ph.D.
- Email: apuigdellivol@cst.cat
- Phone: 34-93-5884555
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COVID19, Influenza Vaccination, ACE Inhibitors, ARB, Antihistamine Allergy, Amantadine